|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 490.68 USD | +0.06% |
|
+3.35% | +7.73% |
Company Valuation: Vertex Pharmaceuticals Incorporated
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55,834 | 74,127 | 104,849 | 103,707 | 115,026 | 124,464 | - | - |
| Change | - | 32.76% | 41.44% | -1.09% | 10.91% | 8.2% | - | - |
| Enterprise Value (EV) 1 | 48,309 | 63,349 | 93,630 | 97,591 | 108,418 | 110,721 | 105,852 | 100,823 |
| Change | - | 31.13% | 47.8% | 4.23% | 11.09% | 2.12% | -4.4% | -4.75% |
| P/E | 24.4x | 22.5x | 29.3x | -194x | 29.6x | 28x | 24.7x | 20.4x |
| PBR | 5.53x | 5.33x | 5.96x | 6.4x | 6.17x | 5.62x | 4.65x | 3.91x |
| PEG | - | 0.5x | 3.51x | 2x | -0x | 1.9x | 1.8x | 1x |
| Capitalization / Revenue | 7.37x | 8.3x | 10.6x | 9.41x | 9.58x | 9.54x | 8.67x | 7.74x |
| EV / Revenue | 6.38x | 7.09x | 9.49x | 8.86x | 9.03x | 8.49x | 7.38x | 6.27x |
| EV / EBITDA | 10.8x | 12.8x | 20.6x | 108x | 19.8x | 19.1x | 15.9x | 13.2x |
| EV / EBIT | 11.1x | 13.2x | 21.4x | 140x | 20.6x | 20x | 16.7x | 13.6x |
| EV / FCF | 20.1x | 16.1x | 28.1x | -123x | 33.9x | 22.4x | 21.7x | 19.6x |
| FCF Yield | 4.99% | 6.2% | 3.56% | -0.81% | 2.95% | 4.47% | 4.6% | 5.09% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 | 17.54 | 19.89 | 24.01 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7,574 | 8,931 | 9,869 | 11,020 | 12,001 | 13,046 | 14,347 | 16,084 |
| EBITDA 1 | 4,470 | 4,941 | 4,556 | 902.8 | 5,473 | 5,789 | 6,650 | 7,648 |
| EBIT 1 | 4,344 | 4,793 | 4,375 | 695.6 | 5,263 | 5,525 | 6,331 | 7,406 |
| Net income 1 | 2,342 | 3,322 | 3,620 | -535.6 | 3,953 | 4,518 | 5,136 | 6,175 |
| Net Debt 1 | -7,525 | -10,778 | -11,218 | -6,116 | -6,608 | -13,743 | -18,611 | -23,641 |
| Reference price 2 | 219.60 | 288.78 | 406.89 | 402.70 | 453.36 | 490.39 | 490.39 | 490.39 |
| Nbr of stocks (in thousands) | 254,252 | 256,691 | 257,683 | 257,529 | 253,719 | 253,805 | - | - |
| Announcement Date | 1/26/22 A | 2/7/23 A | 2/5/24 A | 2/10/25 A | 2/12/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 27.96x | 8.49x | 19.12x | -.--% | 124B | ||
| 36.25x | 12.94x | 27.18x | 0.55% | 1,089B | ||
| 28.59x | 6.53x | 18.09x | 2.01% | 643B | ||
| 33.13x | 7.75x | 15.94x | 2.61% | 465B | ||
| 20.2x | 4.86x | 12.04x | 2.72% | 359B | ||
| 22.65x | 5.84x | 14.57x | 2.74% | 303B | ||
| 22.03x | 4.53x | 12.8x | 1.93% | 267B | ||
| 14.79x | 5.48x | 11.3x | 3.38% | 226B | ||
| 25.81x | 6.73x | 11.86x | 2.57% | 212B | ||
| -48.4x | 5.8x | 32.01x | 2.45% | 167B | ||
| Average | 18.30x | 6.90x | 17.49x | 2.1% | 385.56B | |
| Weighted average by Cap. | 25.28x | 8.12x | 19.09x | 1.86% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- VRTX Stock
- Valuation Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
















